 |
Women with Diabetes Mellitus Have the Greatest Reduction in Myocardial Infarction Mortality Over the Past Decade: Evaluation of 1, 428,596 Patients Enrolled in the Natioanl Registry of Myocardial Infarction 2, 3 and 4 from 1994-2002Presented by Darren McGuire MD, MHSc
The goal of this analysis was to evaluate short-term mortality trends during the past decade among patients with MI according to DM status, especially among women with DM; trends in the prevalence of DM among MI patients; and trends in the use of evidence-based therapies.
Impact of the Angiotensin-Receptor Blocker Candesartan in Preventing Diabetes in Patients with Heart FailurePresented by Salim Yusuf, DPhil
Inhibitors of the renin-angiotensin-aldosterone system (RAAS) have been shown to prevent the development of diabetes in various groups of patients at increased risk of cardiovascular events. This summary looks at the impact of the angiotensin receptor blocker candesartan in preventing diabetes in patients with heart failure
Percutaneous Pulmonary ValvesPresented by Philipp Bonhoeffer, MD
Non-surgical valve replacement may soon become a reality for the replacement of cardiac valves. For pulmonary valve replacement, data to date suggest that percutaneous delivery of a biological valve is possible, is safe, and may have an important role in managing conduit obstructions and pulmonary regurgitation.
The IL-6 -174G/C polymorphism is a powerful predictor for restenosis after coronary stent implantationPresented by Tanja Kottmann, MD
The aim of this study was to investigate which polymorphisms are significant predictors for restenosis after ST and which mechanisms can be identified to increase restenosis.
Late Breaking Clinical Trials IPresented by Donald Hunninghake, MD
Stefan Hohnloser, MD
Rahul Doshi, MD
Gust Bardy, MD
Christopher Cannon, MD
This summary highlights key data from the PROVE-IT TIMI 22, PAVE, ALLIANCE, SCD-HeFT and DINAMIT trials.
Should Statin Therapy Be Used Routinely in Pediatric Heart Transplant Recipients?Presented by William T. Mahle, MD
It is unclear whether statin therapy should be routinely used in the pediatric heart transplant population. The aim of this retrospective analysis was to determine whether such statin therapy would reduce the risk of developing CAV in these children.
The multicenter evaluation of the everolimus-eluting stent for inhibition of neointimal hyperplasia: Results of the pooled FUTURE I and II trialsPresented by Ricardo A. Costa, MD
This summary looks at a pooled analysis of the FUTURE I and II data, with angiographic endpoints of in-stent late loss and binary restenosis assessed at 6 months follow-up.
|
|
|
